Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Income from Continuing Operations: 2021-2025

Historic Income from Continuing Operations for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Income from Continuing Operations fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 6.57%. This contributed to the annual value of -$41.9 million for FY2024, which is 0.59% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Income from Continuing Operations stood at -$12.1 million for Q3 2025, which was down 23.35% from -$9.8 million recorded in Q2 2025.
  • SAB Biotherapeutics' Income from Continuing Operations' 5-year high stood at $1.4 million during Q1 2021, with a 5-year trough of -$22.9 million in Q4 2023.
  • Its 3-year average for Income from Continuing Operations is -$9.8 million, with a median of -$9.8 million in 2025.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 845.93% in 2023, then soared by 56.50% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Income from Continuing Operations (Quarterly) stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then plummeted by 191.21% to -$22.9 million in 2023, then surged by 56.50% to -$9.9 million in 2024, then decreased by 16.60% to -$12.1 million in 2025.
  • Its Income from Continuing Operations stands at -$12.1 million for Q3 2025, versus -$9.8 million for Q2 2025 and -$10.8 million for Q1 2025.